Overview

Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of UNI91103 intranasal spray for treatment of coronavirus disease 2019 (COVID-19) in asymptomatic or mildly symptomatic adults.
Phase:
Phase 2
Details
Lead Sponsor:
UNION therapeutics
Treatments:
Niclosamide